IL-1 Pathway Inhibition Shows Promise for Severe Myocarditis and Recurrent Pericarditis
Background
Myocarditis is a complex inflammatory syndrome affecting the heart, driven by various triggers from viral infections to autoimmune diseases and immune checkpoint inhibitor (ICI) therapy. Current management is largely supportive, lacking specific disease-modifying treatments. The innate immune response and inflammasome activation, particularly involving IL-1, are central to myocardial injury. Targeting the IL-1 pathway offers a mechanistic rationale for a precision therapeutic strategy, addressing a critical gap in treating this heterogeneous condition.
Study Design
This comprehensive review synthesized preclinical and clinical evidence regarding IL-1 blockade in myocarditis and related inflammatory cardiac syndromes. Researchers systematically evaluated existing literature, including randomized controlled trials, case reports, and small series, to assess the efficacy and safety of IL-1 inhibitors like anakinra. The scope covered diverse etiologies of myocarditis, from viral and autoimmune to ICI-induced, providing a broad perspective on the role of the IL-1 pathway in cardioimmunology.
Results
The immune system, particularly Interleukin-1 (IL-1), is a key mediator linking inflammation to myocardial dysfunction, supported by experimental and translational evidence implicating NLRP3 inflammasome activation. The randomized trial of anakinra in acute myocarditis (ARAMIS) did not improve outcomes in a largely low-risk cohort. However, accumulating case reports and small series suggest potential benefit in fulminant/hyperinflammatory myocarditis and chronic active refractory myocarditis. In contrast, IL-1 inhibitors have robust randomized and real-world evidence in recurrent pericarditis, validating IL-1 pathway engagement as an actionable target. This supports a myo-pericardial inflammatory continuum. > Anti-IL-1 therapies, particularly anakinra, have shown promising efficacy in selected severe and refractory myocarditis cases, with a favorable safety profile.
Key Findings
- IL-1 is a key mediator linking inflammation to myocardial dysfunction in myocarditis, often via
NLRP3 inflammasomeactivation. - The ARAMIS randomized trial of anakinra did not improve outcomes in low-risk acute myocarditis cohorts.
- Case reports and small series suggest anakinra may benefit fulminant/hyperinflammatory and chronic active refractory myocarditis.
- IL-1 inhibitors have robust randomized and real-world evidence for efficacy in recurrent pericarditis.
- Anti-IL-1 therapies, particularly anakinra, demonstrate a favorable safety profile in selected severe cases.
Why It Matters
This review highlights a critical shift towards targeted immunotherapy for myocarditis, moving beyond general immunosuppression. For clinicians, IL-1 inhibitors like anakinra represent a promising, well-tolerated option for severe, refractory myocarditis and recurrent pericarditis, where standard treatments often fall short. While not a first-line for all myocarditis, the evidence supports its use in specific hyperinflammatory phenotypes, suggesting a more personalized approach. This validates the emerging field of cardioimmunology and could lead to new treatment protocols, especially for patients with ICI-induced myocarditis or autoimmune forms. Further robust randomized data are needed to solidify its role in broader myocarditis populations.